List of Therapeutic Companies in Pennsylvania - 155

Abound Bio was acquired by Galapagos. Abound Bio is a US company whose mission is to generate novel antibody-based biological therapeutics to meet unmet medical needs in the fields of cancer and infectious disease. Galapagos acquired Abound Bio in 2022.

Abzyme Therapeutics is a biopharmaceutical company focused on developing modular single domain VHH antibody fragments for immunotherapy using proprietary antibody generation platforms. The company is located in the Eastern Pennsylvania biotechnology/pharmaceutical hub 30-miles west of Philadelphia. Unique to Abzyme is our proprietary and highly engineered eukaryotic in vitro antibody discovery/optimization platform based on yeast display self-diversifying libraries, rapid target-directed antibody affinity maturation in combination with a FACS single cell sorting approach to identify desired antibodies. Abzyme’s modular antibody discovery platform incorporates a real-time screening ability to select for key properties such as epitopic diversity, binding affinity, expressibility, solubility, developability, broad-reactivity and target-specificity. Today, the Company has over 60 proprietary and partnered programs in development in therapeutic and diagnostic areas including infectious diseases, immuno-oncology, ophthalmology, inflammation and central nervous system disorders.

Accelerated Biosciences Corp. is commercializing human trophoblast stem cells isolated from the trophectoderm of embryos from women with ectopic pregnancies. hTSCs are ethically sourced and have immune-privileged characteristics. It is an abundant and dynamic pluripotent stem cell platform for basic research, disease modeling, toxicology, drug discovery, and cell therapy.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.

Adaptimmune is a fully integrated cell therapy company, designed and built from the ground up with four U.K.- and U.S.-based biotechnology hub locations. Our comprehensive capabilities and teams include preclinical research, clinical development, translational sciences, autologous and allogeneic manufacturing, and in-house commercial and corporate operations. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Philadelphia, Pennsylvania.

Amyndas is a pharmaceutical company developing potent complement therapeutics for inflammatory diseases and disorders based on its patented technology for modulating the complement system.

At Annovis Bio, Inc., we are pioneering a novel approach to fighting chronic and acute neurodegeneration, offering new hope against the largest unmet need of our aging population - Alzheimer’s and Parkinson’s diseases. Our diverse pipeline also targets such neurodegenerative conditions as traumatic brain injury (TBI), stroke, Down Syndrome, Huntington disease, and mental illnesses. Our lead compound, buntanetap, is a small, once-daily, orally administered, brain-penetrant inhibitor of neurotoxic proteins. The biological activity of buntanetap has been evaluated in 19 animal studies conducted in leading institutions such as the Karolinska Institute, Columbia University, and Harvard University. We have also conducted seven clinical studies in over 1,000 people, which consistently showed that buntanetap is safe and well-tolerated. Moreover, buntanetap has shown the ability to normalize levels of several neurotoxic proteins – APP, tau, aSYN – to those seen in healthy volunteers. In our late-stage trials, buntanetap significantly improved cognitive functions (ADAS-Cog11) in patients with mild Alzheimer’s disease, halted cognitive decline in Parkinson’s patients, and improved motor and non-motor Parkinson’s-related functions (MDS-UPDRS) in several disease subpopulations. We are currently in the process of submitting our latest data to the FDA and planning two pivotal Phase 3 studies—one for Alzheimer’s and one for Parkinson’s. We believe that buntanetap holds the potential to be the first drug to address the underlying mechanisms of neurodegeneration, heralding a new era in the treatment of these debilitating diseases.

Aposcience AG aspires to improve the health of patients in need of regenerative medicine by commercially exploiting the therapeutic potential of secretomes derived from white blood cells (PBMCs) isolated from peripheral blood. PBMCs are currently a waste product of all blood transfusion units.

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.

ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.

Develops a software solution, NICUtrition™, to improve thecare of preterm infants by providing quantitative data about gut health, allowing for personalized care and nutrition to optimize growth and outcomes.

AUM BioTech is a Philadelphia based biotechnology company that offers next-generation genetic research tools in the area of gene silencing and regulation. AUM's products are globally being used by biomedical scientists and researchers working on basic, transitional and pre-clinical research. We invite you to speak with our scientific team to discuss your research needs. Book a web meeting today: https://calendly.com/d/2r6-y62-b7h/invitation-for-rna-silencing-scientific-consultation

AUM LifeTech is an American Biotechnology company focused on using next-generation RNA silencing technology to develop solutions in diverse life science verticals including biomedical research, medicine, agriculture, and aquaculture. Specifically, AUM's custom products include next generation of innovative genetic tools in the area of gene silencing and manipulation for biomedical research and therapeutic development. AUM’s non-GMO products are also being developed for broad-spectrum target-specific pest management and disease control in agriculture. RNA silencing products using FANA technology provide superior alternatives to conventional RNAi and gene editing approaches like CRISPR and provide a fast track target discovery. AUM's goal is to provide innovation at the genetic level for a better life.

Avammune Therapeutics is a drug discovery company focused on the development of novel immunotherapeutics to address high unmet medical needs. Our research is driven by the science that have a potential to create a significant difference on the disease platform. Our expertise lies on developing small molecule drugs that can be administered systemically and can potentially overcome the issues faced by the currently available therapeutics for cancer and immunological disorders. We work with experts in disease biology to achieve this goal which aims at improving the lives of patients significantly. Our research efforts has led to successful completion of projects in the immunoncology space.

Specialty oncology-focused biopharmaceutical company based in Malvern, PA with a broad pipeline encompassing novel best in class selective HDAC6i immunomodulators and a game changing myeloid based discovery platform. Avstera focuses on foundational tumor biology science, while methodologically breaking barriers using cutting-edge approaches in order to deliver impactful treatments to cancer patients.

Axonova Medical is pursuing a disruptive technology that can effectively recreate lost or damaged neural circuitry following neurological injuries. They are a developer of tissue engineered nerve grafts for nerve repair.

Azome Therapeutics is an early-stage drug discovery company focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases. Our lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks a key upstream priming signal involved in the aberrant activation of the NLRP3 inflammatory cascade.

At Best nomos we design products and solutions that help medical professionals treat a variety of cancers. We are best known for our innovations in IMRT and IGRT. As one of the newest members of the Best family of companies, our aim is to expand our product selection beyond imaging technology to become the Single Source Oncology Solutions provider of choice for our customers.

BHS’s vision is to deliver safe and effective biologic drugs to patients everywhere. Our mission is to harness science for the precise design and development of breakthrough biologic medicines.

OUR MISSION: To improve the lives of individuals and their families through engaging, evidenced-based digital adjunctive therapies. Our initial focus is ABA Therapy for Autism Spectrum Disorder (ASD) See the pilot study published in the Journal of Autism and Developmental Disorders on June 1, 2021. https://pubmed.ncbi.nlm.nih.gov/34060003 Sosnowski, D.W., Stough, C.O., Weiss, M.J. et al. Brief Report: A Novel Digital Therapeutic that Combines Applied Behavior Analysis with Gaze-Contingent Eye Tracking to Improve Emotion Recognition in Children with Autism Spectrum Disorder. J Autism Dev Disord (2021). https://doi.org/10.1007/s10803-021-05101-w

BlueSphere Bio was founded to unlock the potential of personalized T cell therapy for the treatment of cancer by harnessing the unique specificity of each patient’s own T cells for the particular molecular fingerprint of each patient’s own cancer through our novel TCXpress technology. Our proprietary TCXpress platform is an elegant, rapid approach that exploits the patient’s own immune defenses to attack their cancer specifically, and is designed to leave normal tissues untouched, thereby reducing harmful side effects. The platform and implementation allows us to deliver rapid, personalized T cell treatments for a variety of cancer indications.

BlueWhale Bio is dedicated to accelerating the growth and adoption of cell-based therapies. With the demand for cell therapy products surpassing supply, BlueWhale Bio aims to address critical shortcomings in the current treatment paradigm. The company is developing a portfolio of groundbreaking products that bring the full benefits of cell therapy to more patients faster and at lower costs.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in combination with a PD-1 inhibitor, retifanlimab (provided by Incyte under a collaboration agreement). Additionally, BriaCell is developing Bria-OTS™, the first “off-the-shelf” personalized immunotherapy for advanced breast cancer.

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company’s lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Cagent Vascular (Wayne, PA) has developed and commercialized its novel angioplasty balloon with Serration Technology to treat blocked arteries in the leg or Peripheral Artery Disease (PAD) and Chronic Limb Threatening Ischemia (CLTI). The Serranator PTA Serration Balloon Catheter is the first and only angioplasty balloon with serration technology

Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA.

Castle Creek Biosciences, Inc., a late-stage cell and gene therapy company, is using two lentiviral platforms to develop and commercialize therapies for genetic diseases.

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company’s lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. Century Therapeutics, Inc. has a research collaboration with Outpace Bio, Inc. for CAR engineering. The company was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Chimeron Bio is a biotechnology company focused on developing personalized gene therapies, including self-amplifying RNA vaccines and therapeutics designed on its proprietary technology.

Code Bio is developing a transformational, new class of precision genetic medicines to treat life-threatening diseases.

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) is a biopharmaceutical company developing innovative cell therapy platforms for patients with cancer.

Consegna Pharma Inc. is a specialty pharmaceutical company with a mission to create best-in-class long-acting medications.

Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, visit www.contexttherapeutics.com.

Cook MyoSite is on a mission to make regenerative medicine a part of everyday medicine. As an industry leader in muscle cell technology, we’re establishing new paradigms for muscle-related disorders. Established in 2002, Cook MyoSite was created to guide the Cook Group organization into the expanding world of cellular technologies. We’re proud to be a part of the vibrant medical community in Pittsburgh, Pennsylvania.

CSL Behring is a biopharmaceutical company that manufactures plasma-derived and recombinant therapeutic products.COVID-19: CSL says it is working on a plasma-based therapy for patients with more severe forms of COVID-19.The company is part of the CSL family of companies. The parent company, CSL Limited is based in Melbourne, Australia, employs more than 30,000 people, and delivers its life-saving therapies to people in more than 100 countries.

Curadh is pioneering the eradication of solid tumors through the new science of molecularly targeted radiation. With expertise in transitioning from Pre-Clinical to the Clinic, Curadh incorporates scientific excellence and product development strategy.

CytoAgents is developing innovative pharmaceutical products to treat life-threatening conditions, diseases, and disorders associated with Cytokine Release Syndrome (CRS). Led by CEO Teresa Whalen, CytoAgents is comprised of seasoned business leaders and medical professionals focused on developing innovative treatments. The company is a clinical-stage biotechnology company with a therapeutic focus on oncology.

Peptides

Diverse Biotech is an innovative, clinical-stage biopharmaceutical research company that is committed to discovering and developing novel therapeutics from its proprietary drug platform.

Advancing regenerative medicine through the development of a natural biomaterial that restores mother nature’s template to treat disease and injury. ECM scaffolds, in solid form, have been successfully used in more than 10 million human patients to repair a variety of body systems such as musculoskeletal tissues, cardiovascular structures, and non-healing skin wounds, among others. These products have all received FDA clearance. ECM Therapeutics'​ patented ECM hydrogel technology allows for expanded, less invasive applications in multiple disease areas. The first clinical product, EsophaGel, treats Barrett’s esophagus, a precancerous condition that currently has no effective therapy.

Headquartered in Malvern, Pennsylvania, Encore Dermatology, Inc. is a privately held fully-integrated dermatology company with a mission committed to delivering innovative prescription therapies and medical devices to dermatologists focusing on customer service and improving the quality-of-life of patients.

At Endo, our far-reaching vision is simple: to help everyone we serve live their best life. As a specialty pharmaceutical company, we’re motivated by a strong sense of purpose to find better ways to meet unique medical needs. Our global team of passionate employees understands the importance of their work. We’re dedicated to supporting one another as we connect with communities and foster partnerships that elevate quality-of-life and bring the best treatments forward. Our uncompromising commitment results in the delivery of life-enhancing therapies. From intelligent product selection to commercialization, we strive to make a meaningful, tangible impact to help everyone live their best life. Endo has global headquarters in Malvern, Pennsylvania. Community Guidelines: 1. Be respectful. Everyone who visits our page should feel comfortable and respected. 2. If we see a comment that violates anything in the following list, it may be removed. • Comments that use profanity; personally attack or bully another individual; or are off-topic, misleading, factually inaccurate, political, spam, defamatory, discriminatory or promotional. • Comments that are excessively repetitive and/or disruptive to the community. • Comments that promote illegal activity, use copyrights or trademarks or are related to an ongoing legal matter. • Comments that appear to be medical advice. We reserve the right to remove a reply for any reason at any time. 3. Adverse Event Reporting: If we see a post about an adverse event, an Endo representative will need to contact you to find out more information to comply with regulatory guidelines. If you experience a side effect while using an Endo product, please consult your physician or pharmacist immediately. You may also report to the FDA at fda.gov/medwatch or 800-FDA-1088. Replies from other users do not necessarily reflect the views of Endo. We do not endorse content added by other users.

Enterin is the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. We are pioneering the medical community’s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson’s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson’s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis and improve quality of life of patients with Parkinson’s Disease and other neurodegenerative conditions.

EpiVario is a preclinical stage biotechnology company focusing on neuropsychiatric disorders. Our co-founders, Dr. Shelley Berger and Dr. Philipp Mews, are leaders in the field of neuroepigenetics. They identified a key metabolic enzyme that functions within the nucleus of neurons to activate genes critical for long term memory. This epigenetic mechanism plays a critical role in consolidating trauma-induced fear and stress responses and drug craving associated with addiction. Thus, providing a new target for treating memory-related neuropsychiatric disorders, such as PTSD and drug and alcohol addiction, and starting with nicotine addiction. An Expert Team Founded by epigeneticists at the University of Pennsylvania, EpiVario’s team leverages deep expertise in epigenetics and neuroscience, along with the commercialization of novel drugs. EpiVario’s co-founders are known and respected leaders in their fields, with more than 30 years of combined experience. A Strong Intellectual Property Portfolio EpiVario currently has PCT and U.S. patents pending, both related to the Company’s novel approach to targeting the ACSS2 gene. About Addiction and PTSD PTSD is a psychiatric disorder that can develop as a response to experiencing or witnessing a traumatic event, such as interpersonal violence, combat, or a life-threatening accident or natural disaster. Core features of PTSD include re-experiencing symptoms (i.e., intrusive memories, flashbacks, and nightmares), avoidance of reminders of the trauma, negative thoughts and feelings (e.g., amnesia for aspects of the trauma, anhedonia, withdrawal, exaggerated self-blame), and increased arousal (i.e., insomnia, irritability, poor concentration, hypervigilance). The severity of PTSD symptoms can intensify through cycles of memory recall and reconsolidation.

Every Cure is a nonprofit initiative on a mission to unlock the full potential of existing medicines to treat every disease and every patient they possibly can.

As a company, we are breathing new life into the regenerative therapeutics market. Our agile and highly experienced team works tirelessly to develop faster, better and easier ways to get our doctors and patients the products and services they need. Every day, we partner with the world's leading medical and scientific experts to drive innovation out of the laboratory and into the treatment room. At the same time, we transform the complexity of reimbursement into a process that's simple and clear for all. We are Evolution. We transform lives.

Fore Biotherapeutics - We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. Deeply rooted in science and innovation, our vision is to compassionately contribute to solving cancer.

Galera Therapeutics is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.

GEMMABio, a new therapeutics company, will serve as the research and innovation arm to speed the research of and global access to life-changing advanced therapies for those living with rare diseases. Alongside Franklin Biolabs, GEMMABio will advance gene therapy research and deliver therapeutics to patients around the world significantly faster.

At Geneos, our passion is to develop personalized therapies to unleash the most powerful force against cancer – your body’s own immune system. Our GT-EPIC Platform is designed to identify relevant neoantigen targets and then design, manufacture, and deliver tumor specific neoantigen-targeted personalized immunotherapies.

Globin Solutions, Inc. is a pre-clinical stage biopharmaceutical company that is committed to researching and developing a rapidly acting antidote for carbon monoxide poisoning, the most common human poisoning. Globin intends to aggressively develop its lead compound through preclinical testing with the goal to pursue regulatory clearance for clinical testing. Globin plans to partner with experts in globin chemistry and protein engineering through sponsored research agreements with the University of Pittsburgh to further develop their pipeline of agents for CO poisoning and other indications.

Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Rooted deep in empathy for patients’ needs and driven by novel science, visionary thinking, and an unwavering commitment to those who feel overlooked, Harmony Biosciences is helping patients thrive by cultivating the growth of innovation that’s essential to advancing life-changing treatments. Visit us: https://www.harmonybiosciences.com/ Follow us: @Harmonybio on X and @harmony_biosciences on Instagram View community guidelines: https://bit.ly/3KYPBSS

Helexva operates as a biotech company that specializes in treatment for fatal neurodegenerative diseases.

Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS). PoNS™, short for Portable Neuromodulation Stimulator, is an innovative medical device. It is inclusive of a controller and mouthpiece, that delivers mild stimulation to the surface of the tongue. This stimulation triggers a flow of neural impulses to the brain structures that control balance and gait. PoNS is meant to be used in conjunction with supervised therapeutic activity, referred to as, PoNS Therapy™. Use of the device while engaging in movement and coordination tasks promotes neuromodulation, activating brain pathways to help improve balance and gait. PoNS is authorized in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. PoNS is authorized in Canada for three indications: (i) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (ii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke, to be used in conjunction with physical therapy. PoNS is authorized in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait.

i3 Pharmaceuticals' mission is to develop, manufacture and bring to market high-quality, difficult to formulate, high technological barrier solid oral specialty pharmaceutical products. As a company, i3 Pharmaceuticals' drive for excellence arises from the company's core values: Insight into markets and products, Ingenuity in product selection and development, and Integrity in our partnerships, with an uncompromising dedication to product quality.

iECURE is a clinical-stage biotechnology company focused on delivering cures and transforming the lives of patients with devastating liver disorders, utilizing new advancements in genetic medicine. We are advancing our pipeline in close partnership with the world-class translational engine at the University of Pennsylvania’s Gene Therapy Program. Using in vivo editing, our methods focus on inserting functioning genes into patients’ genomes, which offers long-term, stable expression of those genes. With our team’s proven track record, as well as the University of Pennsylvania’s deep expertise and translational genetic medicine engine, reversing the course of these devastating diseases is now within reach.

Imagine Pharma is a biotechnology company focused on three distinctive platforms: oral delivery, regenerative and therapeutics. Each platform has first-in-class programs that address multiple disease states in large underserved markets.

Immunome Inc., a biotechnology company, discovers, develops, and commercializes highly targeted and native human cancer antibodies against universal cancer antigens. Its RealMAb technology enables the discovery of novel antigens and the cognate native human antibodies that target antigens; and ScreenMab multiplex functional screening technology identifies monoclonal antibodies that have exquisite for tumor neoantigens. The company was founded in 2006 and is based in Exton, Pennsylvania.

Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies. Imvax’s combination therapy uniquely captures the complete antigenic signature of a patient’s own tumor and converts it into a highly stimulatory ‘training program’ for the patient’s immune system. The comprehensive nature of this training is intended to result in both innate and adaptive immune stimulation to optimize long-term anti-tumor effects. The company’s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer, with additional programs in other types of solid tumors.

Innate Biologics, LLC is a privately held company targeting, treating and preventing inflammation through the development of a first-of-its-kind recombinant protein platform, which specifically targets intracellular inflammatory signaling pathways.

INOVIO is a biotechnology company committed to powering a new way forward in DNA medicines to save and protect lives worldwide. The company is focused on rapidly bringing to market precisely designed and delivered DNA medicines to potentially treat and protect people from serious and life-threatening diseases associated with HPV, cancer, and infectious diseases.

Integral Molecular is a research-driven biotechnology company specializing in antibodies, viruses, and membrane proteins. We develop technologies for solving big scientific challenges and advancing therapies against difficult-to-treat diseases. Our products, platforms, and services enable antibody discovery, biotherapeutic safety profiling, vaccine development, protein engineering, and more. Learn why top pharmaceutical and biotechnology companies trust Integral Molecular. Instagram: IntegralMolecular

To make bold and positive change in the biomedical and technology markets. An innovation hub, we relentlessly pursue ideas and inventions that result in superior products, processes, and design. This relentless pursuit drives us every day to bring ideas to market that improve lives and give back to the communities in which we operate.

Interius is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next-generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania.

IO Biosciences develops allogeneic, gene modified cell therapies that treat cancers. Leveraging a proprietary lifesaving gene editing system and cell source, we create a unique opportunity to develop and manufacture of-the-shelf gene modified cell therapies. Taking vision from concept to reality - literally starting as a virtual, home-based biotech start-up last year, IO Biosciences has evolved to a team of 5 with office space and lab facility. Our state of the art CRISPOR gene editing methods create a new generation of universal “plug and play” cell sources for research and gene modified cell therapies treating cancers. This innovative system allows current personalized therapies to be transformed into manufactured off-the-shelf treatments and will greatly improve patient access at a competitive price point.

KaliVir Immunotherapeutics was founded in 2019 to pioneer a unique and novel approach to cancer treatment that engages a virus' natural ability to replicate in and kill cancer cells. This modality is known as oncolytic viral immunotherapy. KaliVir's cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh's world-class oncolytic virus and immunotherapy research programs.

Kannalife Sciences, Inc. ("Kannalife"), is a pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer ("NIH-OTT") for the Commercialization of U.S. Patent #6630507, "Cannabinoids as Antioxidants and Neuroprotectants" (the "‘507 Patent"). Further, Kannalife has developed its own patented molecules lead by KLS-13019 called by TIME Magazine/SI as a "super-CBD" and was recently awarded U.S. Patent #9611213, "Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy et al.". Kannalife is currently conducting research and development at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, to treat Hepatic Encephalopathy ("HE"), Chronic Traumatic Encephalopathy ("CTE") and Chemotherapy Induced Peripheral Neuropathy ("CIPN"​). <​iframe width="560"​ height="315"​ src​="https://www.youtube.com/embed/LWLbe9m4JWo"​ frameborder="0"​ allow="autoplay; encrypted-media"​ allowfullscreen><​/iframe>

Kannalife Sciences, Inc. (a subsidiary of Neuropathix, Inc.) is a biopharmaceutical company focused on the research and development of a pipeline of next-generation pharmaceutical and phyto-medical products. The company is based in Doylestown, Pennsylvania and is known for its globally patented anti-inflammatory technology. Kannalife Sciences, Inc. is dedicated to the development of breakthrough therapeutics targeted for the treatment of inflammation and neurodegenerative diseases.

Kibow® Biotech is a biotechnology company founded in 1997, based in suburban Philadelphia and specializing in the development and commercialization of scientifically-formulated and clinically-tested probiotic and prebiotic dietary supplements. Kibow® specializes in probiotic supplements for maintaining kidney health, supporting immunity, cardio health, digestive health, and general wellness. Established to help fight these rapidly growing health risks, Kibow® provides the highest quality non-drug dietary supplements at affordable prices. Mission Kibow's® mission is to address health needs by utilizing their expertise in proprietary probiotics and functional fibers with extensive scientific and clinical drug-like validation to produce top tier supplements. Vision Our Vision is to advance the welfare of people globally by providing superior probiotic supplements. We will achieve our vision by developing effective, safe, and scientifically proven probiotic formulations. Our products will also be economical and convenient to use. We have already developed several innovative products, and will continue to do so while adhering to our humanitarian and social values.

Krystal Biotech, Inc. is using gene therapy to develop effective and novel treatments for skin diseases. Our goal is to make a meaningful difference in the lives of underserved patient populations with debilitating skin diseases. We work to accomplish that through scientific innovation, operational excellence and believe that “nature operates in the shortest way possible”. (Aristotle)

LabyRx Immuno-Oncology is a bio-medical company focused on developing a comprehensive platform for treating adenocarcinomas, a class of glandular-related tumors that represent approximately 40% of worldwide cancer cases and 50% of treatment-related spending. Based upon our scientists' discovery and ongoing research into the unique adenocarcinoma target – Labyrinthin – the Company aims to advance novel cancer therapeutic technologies that improve treatment processes. The team comprise renown scientists in the United States and Hong Kong working towards cancer therapeutics and diagnostics.

Larimar Therapeutics, Inc. (Nasdaq:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich’s ataxia (FA). Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

At Latus Bio, we are developing novel therapeutics for CNS disorders with our revolutionary AAV capsids. We have developed capsid variants with unprecedented potency, specificity, and trophism. All of our capsids were designed with a particular disease in mind, in order to find the right capsid and the right route of administration to target the most relevant brain regions and cell types for each specific indication. Founded on the groundbreaking work of Professor Beverly Davidson from the Children's Hospital of Philadelphia, Latus Bio is committed to transforming patient care through targeted, potent, and safe gene therapies. We are focused on CNS diseases such as CLN2 (Batten Disease) and Huntington’s Disease, aiming to fundamentally alter the course of these challenging conditions by always putting the patients first. We are not just developing therapies; we are revolutionizing the future of healthcare with innovations that reduce therapeutic load, enhance safety, facilitate manufacturing, and expand access. Latus Bio is powered by a diverse team of visionary scientists, clinicians, and industry leaders dedicated to tackling some of the most complex neurological disorders. With a robust pipeline and a strategy to enter clinical trials by late 2025, we are poised to make significant strides quickly. Be part of this transformative movement at Latus Bio. Let's unlock the potential of gene therapy to bring hope and healing to millions around the globe. Learn more about our mission, our people, and our promise at www.latusbio.com and connect with us on LinkedIn to follow our progress.

Levolta Pharmaceuticals is a biopharmaceutical company that offers a portfolio of early-stage small molecules and late-stage novel formulated compounds for various medical fields, including rheumatology, the central nervous system, oncology, and immunology.

LifeLens was founded in 2014 by Dr. Robert Schwartz, Landy Toth, David Robins, and Dr. Robert Van Tassel. Its mission is to create simple, commercially viable technologies for high fidelity physiologic monitoring.

Lipella Pharmaceuticals, Inc. is a biotechnology company with a focus on supportive care to cancer survivors who acquire hemorrhagic cystitis. They are a clinical-stage pharmaceutical company with expertise in drug delivery and the treatment of urologic conditions.

TandemLife is a medical device company that develops a circulatory system to provide support for patients during cardiopulmonary bypass procedures.

Longevity Biotech, Inc is a company that specializes in breakthrough peptide technology. They are focused on developing a new class of drug candidates called Hybridtides® that deliver unique product profiles. The company is currently in preclinical development.

LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient’s lymph nodes to be used as bioreactors to regrow functioning ectopic organs. LyGenesis’ lead preclinical program is focused on liver regeneration for patients with end stage liver disease. Other therapeutic targets for organ regeneration include the thymus, pancreas, and kidney. Privately held, LyGenesis is headquartered in Pittsburgh, Pennsylvania.

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy.

Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, and postpartum depression. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

MAXONA Pharmaceuticals, Inc. is a privately held, clinical stage, specialty pharmaceutical company focused on the development and commercialization of a portfolio of novel therapeutics for the treatment of pain in the United States. MAXONA is developing MAX-001 as the first novel therapeutic alternative to opioids and NSAIDs for the treatment of pain. While the U.S. is currently experiencing an opioid abuse epidemic, there has been very limited innovation to address the needs of millions of Americans suffering from acute and chronic pain. Hence, there is a significant need for safe and efficacious alternative analgesics. MAX-001 is an ex-US marketed non-opioid, non-NSAID analgesic New Molecular Entity which aims to fundamentally address the short-comings of existing therapies. MAXONA has assembled a highly experienced and well recognized management team with a proven record of successfully developing and commercializing effective therapeutics. We are committed to developing novel therapies for treating pain...without compromise.

Medicus Pharma Ltd. (TSXV:MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. Through our diverse experience and extensive industry network, we are building Medicus into a leading pharmaceutical company, committed to deliver better treatment outcomes and alleviate pain and suffering. Utilizing a thesis driven collaborative process, we identify, acquire and advance relatively de-risked clinical stage assets through clinical development and commercialization. We look into opportunities where an unmet need exists for improved patient safety and efficacy. Medicus is opportunisticly exploring to expand its drug development pipeline through qualified and accretive acquisitions and partnerships. Our portfolio of companies include Skinject, Inc.

Medunik USA is dedicated to providing Americans suffering from rare diseases with access to orphan drugs that are not currently available in the U.S. We make these treatment options available by building strategic partnerships with international companies to bring their products to the American market. Through in-licensing partnerships, Medunik USA offers turn-key operations and provides medical scientific liaisons, approval and market access processes and marketing for orphan disease treatments. Medunik USA is part of the Duchesnay group, which consists of five pharmaceutical companies to meet the needs of patients in Canada, the U.S. and abroad. In 2009, the company launched Medunik Canada to bring orphan drugs to Canadians with rare diseases. Today, Medunik USA brings orphan drugs to the U.S. market to provide Americans with rare diseases with the life-changing and potentially life-saving treatment options they deserve.

Mid-Atlantic BioTherapeutics (MABT) was founded in 2011 with the mission of eradicating terrible infectious diseases using a novel, patented technology platform called IMT504. IMT504 harnesses the body’s own immune response to fight off infections that would otherwise be difficult or impossible to treat. IMT504 has shown impressive results in animal safety and efficacy models, and in humans. IMT504 is a truly revolutionary, proprietary molecule with an impressive safety and immunostimulatory profile in humans and multiple primate models. The immune system-based therapy that IMT504 uses is called “immunotherapy”. Our focus on immunotherapy offers partnering and collaboration opportunities in the area of Infectious Disease applications. Fundamentally, we are a clinical-stage pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. We are actively addressing the growing antibiotic resistance problems and creating a revolutionary treatment paradigm for viral diseases (eg, Tamiflu alternative for influenza), emerging infectious diseases and biodefense. In addition, MABT is the first company to have received a valuable regulatory incentive called Orphan Drug Designation for late-stage rabies disease. Orphan Drug Designation offers a unique opportunity for ensuring a more rapid, efficient pathway to FDA approval and extended market exclusivity. Since the company’s inception, the founders have been responsible for funding the development of the IMT504 technology platform, investing over $23M to date. They continue to invest in this promising new therapy to develop therapies to impact disease with innovative treatments.

At Mineralys Therapeutics we aim to redefine hypertension diagnosis, management and treatment. We are driven to break the “trial and failure” approach to hypertension management and bring a personalized approach to the management of hypertension.

NanoCell Therapeutics is a privately-held biotechnology company with offices in King of Prussia, Pennsylvania, and Utrecht, the Netherlands. Our mission is to revolutionize in-vivo cell engineering through our groundbreaking non-viral, DNA-based gene therapy platform, primarily focusing on oncology and autoimmune diseases. At NanoCell, we’re driving innovation by transforming traditional adoptive cell therapy methods into advanced in-vivo treatments. Our ultimate goal is to simplify the treatment process, increasing patient accessibility, potential clinical benefits, and cost-effective manufacturing. We work both autonomously and in collaboration with partners to make substantial advancements in our targeted disease areas. For more information, visit http://www.nanocelltx.com).

Navrogen Inc. is a biopharmaceutical company focused on the targeted treatment of cancer. Navrogen is currently working on enhancing the immune system to fight cancer by removing the effect of factors produced or induced by tumor cells which inhibit the cancer-fighting humoral immune system.

NephroDI Therapeutics is a pre-clinical development stage biopharmaceutical company that focuses on concentration disorders of the kidney. The initial clinical indication for its orally administered lead small molecule is for Nephrogenic Diabetes Insipidus in children, a pediatric orphan indication. Nephrogenic Diabetes Insipidus (NDI) is a disease where patients produce extremely large amounts of dilute urine resulting from an inability of the kidney to respond to vasopressin. Congenital NDI in the pediatric population results primarily from mutations in the type 2 vasopressin receptor, which is located on the X chromosome. Congenital NDI has a profound impact on children. Since these children can produce up to 20 L of urine per day, They must drink 20 L (80 8oz glasses) of water per day to avoid dehydration. Children who suffer multiple episodes of severe dehydration often end up with mental retardation. For more information visit www.nephrodi.com

NeuExcell Therapeutics is a gene therapy company focusing on improving the lives of patients suffering from neurodegenerative diseases. We have discovered a disruptive technology that focuses on regenerating neurons in the brain. This powerful platform has the potential to transform patient outcomes and change lives. We are now rapidly expanding our R&D efforts, toward our goal of developing effective and safe treatments for serious neurodegenerative diseases including stroke, Huntington’s Disease, ALS, and Traumatic Brain Injury. Our experienced team is excited to dedicate themselves to contribute and bring innovative and effective treatments for those suffering from neurodegenerative conditions. It is our goal to improve the quality of life of millions of patients worldwide by using the power of gene therapy to restore damaged neuronal tissue.

Neuraptive Therapeutics is a medical technology company that specializes in bringing novel therapeutic technology for the acute surgical repair of injured peripheral nerves.

Neuronasal is a pharmaceutical company that specializes in a novel nose to brain drug delivery route for n-acetylcysteine (NAC) with patent protection and proven efficacy in delivering drugs to specific brain regions.

Novasenta discovers novel therapeutic targets to develop innovative and effective treatments with the goal of transforming the lives of patients with cancer

Noveome Biotherapeutics, Inc. is a clinical stage company focused on breakthrough therapies for the regenerative repair of inflamed or damaged tissues. The company, originally founded as Stemnion, Inc., is located in the heart of Pittsburgh near the Southside Works. Noveome is passionate about growing its business in Allegheny County and helping the region to become a world leader in biotherapeutic research and development. Noveome Biotherapeutics, Inc. is a dynamic biopharmaceutical company with an innovative platform technology that represents a paradigm shift in drug development. Unlike most drugs that are single molecules directed at specific indications, Noveome’s product is a complex mixture of biomolecules that is believed to have the ability to treat a wide range of conditions and injuries. Noveome collaborates with major research centers to advance these therapeutic applications.

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company’s product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

Opsidio is a biotechnology company that develops novel biologic therapeutics for patients suffering from fibrotic and allergic diseases. They are passionate about developing remedies for the millions of people affected by the damaging effects of chronic inflammation.

We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System™ (EDS®) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018. In March and June 2022, we announced positive top line results from our two Phase 3b clinical trials (ReOpen1 and ReOpen2) of XHANCE for a follow-on indication for the treatment of chronic sinusitis. In February 2023, we submitted a prior approval efficacy supplement (sNDA) to support the approval of a new indication for XHANCE for the treatment of chronic rhinosinusitis. If the sNDA is approved, XHANCE has the potential to be the first drug therapy approved by the FDA for the treatment of chronic sinusitis. As of February 20, 2023, we had a total of 141 full-time employees all of whom are in the United States, and no part-time employees. Culture is a critical element in the management of our organization. Our colleagues are focused on driving our business with the Optinose values as the foundation for all our efforts. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives. Our values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance and Possibility Thinking guide our actions and decisions.

Orchestra BioMed biomedical innovation company focused on developing transformative therapeutic products for large unmet clinical needs in procedure-based medicine.

Organoid Therapeutics is developing organoid-based technologies to correct hormone deficiencies in patients and streamline drug discovery and toxicology testing in the lab.

Palvella Therapeutics (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations. For more information, please go to www.palvellatx.com.

Panorama Medicine is a VC-backed startup founded by a multidisciplinary team of world-renowned computational and experimental RNA biologists. Panorama has created PAN, a drug discovery platform that integrates genomics, big data, and computing to develop therapeutic interventions for RNA defects in disease. Research by Panorama and other companies has demonstrated that aberrant RNA splicing underlies a significant number of human diseases. Building industry leading algorithms and vast amount of public and proprietary datasets, Panorama has built the PAN platform to predict splicing events as well as design and screen modalities to address the underlying causes. We look forward to collaboration with the global drug development community to advance medicine and contribute to human knowledge of biology.

The Lubrizol Corporation, a Berkshire Hathaway company, is a specialty chemical company whose science delivers sustainable solutions to advance mobility, improve wellbeing and enhance modern life. Founded in 1928, Lubrizol owns and operates more than 100 manufacturing facilities, sales and technical offices around the world and has more than 8,000 employees. For more information, visit www.Lubrizol.com.

Passage Bio is a genetic medicines company based in Philadelphia, PA that is developing a deep pipeline of adeno-associated virus (AAV) delivered therapeutics for the treatment of rare monogenic central nervous system disorders (CNS). We seek to deliver transformative therapies to patients by leveraging our team’s decades of experience, including our founders, as well as the transformative potential genetic medicine technology to develop treatments that improve outcomes for patients with serious, life-threatening, rare CNS disorders.

Peptilogics was founded in 2013 to advance novel peptide therapeutics and harness the power of a design-based approach to drug discovery. Our approach bridges untapped chemical space to engineer peptides to treat some of the most challenging diseases. Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics through their computational platform.

At Pera Labs, we develop digiceuticals and ai-powered solutions for difficult health problems such as fertility. The flagship component of our platform technology for fertility treatments is called SPERMAN, an artificial intelligence based sperm sorter system which provides automated solution for time consuming and labor intensive sperm assessment AND sperm selection procedures. SPERMAN helps fertility clinics perform highly accurate sperm assessment and separation in minutes not days. We take a holistic approach to fertility treatments. Therefore, starting from the assessment of sperm and egg cells all the way to newborn screening, our innovative platform technology can provide more efficient and affordable fertility treatment strategies. We are looking for investors, distribution and implementation partners. Join us for making fertility journey affordable and efficient.

Peroxitech is a privately held emerging biopharmaceutical company focused on the development and commercialization of a novel peptide for treating acute lung injury (ALI). The company has secured seed financing and Series A financing to advance its treatment for ALI, and has been awarded an NIH grant to develop a novel therapeutic approach to expand and improve the lung transplant organ pool.

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells. Testing services for transplant recipients and drug developers are provided at Plexision's CLIA-certified, central laboratory in Pittsburgh. Plexision currently offers cell-based testing for personalized assessment of rejection risk after solid organ transplantation The Pleximmune blood test is the first such test offered for children with liver or intestine transplantation.

Praeventix is an early development stage biopharmaceutical company committed to the discovery, research and early clinical development of novel serotonergic compounds for the treatment of gastrointestinal diseases.

Our mission at Predictive Oncology is to change the landscape of oncology drug discovery and enable the development of more effective therapies in the treatment of cancer. By harnessing the power of machine learning, scientific rigor and biologics, we can improve the probability of success and advance drug compounds with a higher degree of confidence. We invite you to follow us to stay up-to-date about our latest developments.

The convergence of unbiased spatial analytics and explainable AI ushers in a new era of precision pathology. The novel insights from our platforms reveal the existence of intermediate cell types and their functional states as well as communications between cells. Our solutions empower clinicians/researchers to accelerate drug discovery, optimize clinical trials, advance companion diagnostics, personalize therapeutic options, and improve clinical workflows. info@predxbio.com

Prolifagen Therapeutics is a biotech startup dedicated to the prevention of heart failure in patients with large myocardial infarcts. The company is focused on cardiac regeneration based on microRNA technology.

Puresyn, Inc. is focused on and dedicated to providing manufacturing services capable of producing high quality DNA which can be used for many applications including GMP manufacture of gene therapy products.

Qrono Inc is working on new immunotherapies using our Eloquent platform to target antigen presenting cells and macrophages. Sign up on our website for updates.

Developing surgical solutions to improve peripheral nerve repair: - Accelerating healing following a nerve injury - Improving nerve function following injury and repair

Reunion Neuroscience is a clinical stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions.

RiboNova is a privately-held biopharmaceutical company based in the Lankenau Institute for Medical Research near Philadelphia, Pennsylvania. Their product pipeline includes a Phase-2 ready small molecule drug for the treatment of all forms of genetically-confirmed mitochondrial disease and a proprietary drug discovery platform that targets transfer RNA with novel precision medicines for the treatment of mitochondrial and other diseases.

Scout’s mission is to harness the genetic revolution transforming human medicine to deliver the future of veterinary medicine. By combining world-leading talent in animal health and gene therapy technology, we have built a development platform for one-time therapies that address major areas of unmet medical need in pet medicine. We are a global company supported by leading life sciences investors and an R&D collaboration with the renowned Gene Therapy Program at the University of Pennsylvania. About Our Currently Enrolling Study for Cats Scout’s first therapy in development focuses on the anemia associated with chronic kidney disease (CKD) in cats. Our study is currently enrolling cats at participating clinics across the U.S. It involves a single injection (followed by 70 days of monitoring) and may relieve a cat’s anemia for life. Learn more about our study and find a participating clinic: www.scoutbio.co/catEPOstudy.

Seneca Therapeutics was found by Dr. Paul Hallenbeck to develop the Seneca Valley Virus (“SVV-001”), a best in class oncolytic virus. SVV-001 is already in Phase I/II and has a clinical safety record in humans. SVV-001 binds to the TEM8 receptor which is common in many solid tumors like breast cancer, lung cancer and neuroendocrine tumors. SVV-001 is also being considered as a viral vector for gene therapy targeting the TEM8 receptor in solid tumors.

SFA Therapeutics is a clinical stage start-up biotech company developing compounds discovered in human microbiome. This patented and proprietary platform is based on immuno-modulation of inflammatory factors derived from human gut microbiome. The technology is licensed from and supported by research at Temple University in Philadelphia. These products are a unique native immunotherapy platform with activity currently being investigated in cancer, liver, and auto-immune disease.

Imagine a world where genetic diseases are treated with orally-available small molecule drugs. That's the future Sharp Edge Labs is building. Sharp Edge is a preclinical-stage life sciences company developing drugs for genetic diseases. Our monogenic disease focus de-risks the clinical path. Each pipeline program has a genetically identifiable subset of patients and an early Phase IB pharmacodynamic readout. We combine three core techologies to create a scalable platform for discovery and development. CoreX(tm) is s suite of assay technologies that enable the creation of realistic cellular models of genetic diseases. AlloChem(tm) is a proprietary compound library computationally biased to contain molecules that can bind proteins allosterically, stabilizing them, and restoring their function. Disco/Mine(tm) is a suite of computational and machine learning tools that enhances our experimental approach rather than replacing it. These combine to create a scalable platform with over 10 programs at various stages of development. The company has programs in Frontotemporal Dementia, and genetic subsets of Alzheimer’s and Parkinson’s, as well as lysosomal storage disorders and other loss-of-function diseases. The team and its advisors includes ex and current Genzyme/Sanofi, Synageva, Pfizer and Shire executives.

Sigmapharm Laboratories, LLC, a privately held specialty pharmaceutical company, is engaged in the development, manufacturing and marketing of unique generic and branded products. Our company also provides contract development and manufacturing of patentable, stable and maximally bioavailable formulations of new chemical entities. Our products are developed and manufactured using our proprietary drug delivery systems which can effectively optimize drug solubility, bioavailability and stability. Presently, our company and its affiliates control more than seventy (70) formulation patents worldwide. In addition, we are fully integrated (sometimes referred to as ‘backward integrated').

Skinject, Inc. is developing a novel drug delivery system for the treatment of non-melanoma skin cancers. The system comprises a dissolvable microneedle array (MNA) to deliver a drug directly into the top layer of skin. The drug will kill non-melanoma skin cancer by causing an immune system reaction to combat the disease. SkinJect consists of three key components: - Dissolvable microneedles that penetrate the skin, dissolve and deliver the "cargo" − the drug. - A cellulose-like material that forms the microneedles and carries the cargo. It is FDA-approved for human use. - A chemotherapy cargo that kills cells and also stimulates an immunological response from the patient's lesion. Also FDA-approved for human use.

At Spark® Therapeutics, we believe in a world where no life is limited by disease.   We were born of innovation, springing from the curiosity, imagination and dedication of remarkable scientists and healthcare visionaries. Our mission is to unlock the power of gene therapy to accelerate healthcare transformation.     Since our founding, we have been committed to bringing a wide range of expertise to build a fully integrated gene therapy company focused on inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver, such as hemophilia. We are seeking talented individuals with diverse experiences, abilities and interests who have the curiosity, courage and drive to reimagine a new health care paradigm.     Join us on a journey through uncharted territory – seeking to bring gene therapy to people worldwide. The resilience of the people we serve is our inspiration to break barriers, as we strive to turn genes into medicine. Spark® is a member of the Roche Group.     Know that working at Spark Therapeutics is not just another job; it is a once-in-a-lifetime opportunity. We embrace the challenges before us and the uncertainty inherent in them. Ultimately, we are working to create a world where no life is limited by disease. To learn more about Spark and our open positions, visit www.sparktx.com. You can also find us on Twitter at @Spark_tx.  Spark’s social media sites are monitored from Monday to Friday during normal business hours. Questions or concerns should be directed here: https://sparktx.com/contact-us/.

Acquired by Sumitomo Dainippon Pharma of Japan. Spirovant Sciences is a gene therapy company focused on changing the course of cystic fibrosis and other respiratory diseases. The company's current focus is on developing novel gene therapies for cystic fibrosis and other pulmonary diseases. Spirovant is located in Philadelphia, PA's thriving Life Sciences Corridor and has a diverse management team, researchers, and partners.

SteroTherapeutics is pursuing novel drug therapies for orphan diseases, or diseases that are often life-threatening, and which affect fewer than 200,000.

STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing cutting-edge solutions for the in-office treatment of various dermatologic conditions. Backed by decades of experience, STRATA offers an ever-growing portfolio of best-in-class skin science technology, through an innovative partnership approach that advances treatment options for life-altering skin conditions including psoriasis, vitiligo and atopic dermatitis.

Suvoda is a global clinical trial technology company specializing in complex, life-sustaining studies in therapeutic areas like oncology, central nervous system (CNS), and rare diseases. Suvoda empowers sponsors, sites, and patients to manage the most urgent moments in the most urgent trials through advanced IRT, eConsent, eCOA, and ePatient software solutions delivered on a single platform.

Swan NeuroTech is a Pittsburgh-based startup developing biodegradable implants for peripheral nerve injuries.

INNOVATIVE BONE GRAFTS BASED ON IMPROVED BIOACTIVE GLASS Synergy has identified an optimal bioactive glass particle with a spherical shape and a biomodal size range that has been shown to significantly improve bone healing. Synergy's BioSphere® particles have been engineered to maximize the bone healing potential of bioactive glass. Synergy Biomedical is a privately-held medical device company focused on bringing biomaterial based products to the orthopedic and spinal surgery markets. Synergy's BIOSPHERE Technology represents an innovative approach to advancing bone graft technology, and improving bone healing and patient outcomes. Synergy Biomedical welcomes inquiries from independent sales distributors with an understanding of orthopaedic and spinal surgery. We are looking for distributors with a proven track record who are willing to grow our bone graft market. Please visit our website for more information: www.synergybiomedical.com

Targepeutics is a biopharmaceutical company developing selective molecularly targeted therapeutics to fight and diagnose cancer and other diseases. Our lead compound, GB-13, is currently advancing toward a Phase I clinical trial for several cancer targets. GB-13 is a genetically engineered recombinant protein that specifically binds and destroys cancer cells with minimal normal cell damage. We have also licensed related technology for a cancer immunotherapy that is in Phase III clinical trials.

Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.

TerSera Therapeutics is a biopharmaceutical company with a focus in oncology, acute care, and non-opioid pain management. Since 2016, we have come together to build a patient- and people-centric organization transforming therapies to improve human health. We remain committed to continuing to build new cornerstones of care through our portfolio of unique therapeutics, amplifying their ability to deliver meaningful outcomes for patients.

Thera Neuropharmainvestigates the use of small molecules and RNA-based compounds as therapeutics to treat Amyotrophic Lateral Sclerosis (ALS)andTraumatic Brain Injury (TBI).

ThirdLaw Molecular LLC has pioneered the development of Spiroligomer™ molecules and is developing this innovative, patent-protected, therapeutic modality into a new class of more targeted medicines. The mission of the Company is to create a revolutionary category of molecules that transform how diseases are diagnosed and treated – more safely and effectively.

Thrombolex is engaged in the design, development, and distribution of innovative endovascular catheters used in interventional procedures, particularly in pharmaco-mechanical catheter-directed thrombolysis (PM-CDT) in patients who suffer from arterial and venous thromboembolic (A&VTE) conditions. The Company is currently marketing seven (7) different FDA-cleared devices that are all based on the BASHIR™ Endovascular Catheter platform technology.

Tolerance Bio will increase health span by preserving and restoring the function of the thymus, the master regulator of immune tolerance. Immune-mediated diseases represent a significant unmet medical challenge: cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergies.

Traws Pharma is a clinical stage company aiming to address unmet medical needs in respiratory viral diseases and cancer. We leverage broad and deep expertise in small molecule chemistry, artificial intelligence and machine learning, rational drug design & streamlined development to deliver innovative medicines. We target critical threats to human health, aiming to overcome problems caused by acquired resistance to current medications, with an additional focus on vulnerable populations.

Treovir was established in 2019 to develop and commercialize G207, an oncolytic HSV virus for the treatment of pediatric brain tumors. A Phase 1 clinical trial has been completed demonstrating strong evidence of safety and efficacy. Treovir will launch a Phase 2 clinical study for G207 in 2023 that is designed to seek market approval to treat pediatric patients with recurrent pediatric gliomblastoma. Pediatric Brain Tumors are the most common form of solid tumor in children. More than 3,400 children are diagnosed every year. Outcomes for children with high-grade glioma are poor despite surgery, radiation and chemotherapy, which produce devastating neurotoxicities in a child’s developing brain. There has been a complete lack of therapeutic advances in the past 15 years, and the median survival at tumor recurrence is less than 6 months. The G207 therapy consists of a single infusion directly into the tumor. The immunotherapy approach causes direct tumor cell death and also recruits immune system cells to aid the body’s own natural tumor defenses. In a Phase 1 clinical trial in 12 patients, G207 therapy saw Improved overall survival of 12.2 months versus 5.6 months for historical trials. There was also a dramatic safety advantage with no serious adverse events observed. Significantly, evidence of florid T-cell response in treated tumors turning immunologically “cold” tumors “hot” was also observed indicating the body's own immune system was activated against the tumors.

Trevena is a biopharmaceutical company focused on developing and commercializing novel medicines for patients with central nervous system (CNS) disorders.

Uniquity Bio is a clinical-stage drug development company dedicated to advancing scientific innovation to deliver novel medicines for patients with immunology and inflammation conditions.

Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options. Verismo Therapeutic’s core technology is built upon CARs that are uniquely engineered to more realistically reflect the natural multichain design of killer immunoglobulin-like receptors (KIRs), an important family of immunologic receptors used by T cells and NK cells. Preclinical studies show that SynKIR™-T cells, created by introducing these KIR-based CARs (KIR-CARs) into T cells, more effectively eliminate aggressive tumors in vivo when compared with T cells bearing traditional 2nd generation CAR designs found in current FDA approved CAR-T cell therapies.

At Verrica Pharmaceuticals, we are dedicated to easing the strain of hard-to-treat viral skin infections affecting millions of underserved patients. We are initially developing a topical therapy for the treatment of molluscum contagiosum, a highly contagious and primarily pediatric viral skin disease, and common warts. There is currently no FDA-approved treatment nor is there an established standard of care for either of these diseases, resulting in significant undertreated populations in two of the largest unmet needs in dermatology.

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.twitter.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Vibe Pharmaceuticals LLC is an early-stage drug discovery company, spun out of the University of Pennsylvania, developing effective therapeutics for musculoskeletal disorders which lead to bone and muscle loss. The Vibe Pharmaceuticals technology is based on the well-established scientific observation that mechanical stimulation of responsive tissues, including bone and muscle, leads to increases in bone density and muscle mass. The Company team has developed a drug discovery platform for molecules that mediate bone and muscle mass increases and has identified specific proteins, which are being studied as active therapeutic candidates for osteoporosis, sarcopenia and related indications.

Virpax Pharmaceuticals specializes in developing novel and proprietary drug delivery systems

At Vitara, we are working to offer preterm newborns and their families a lifetime of possibilities. We seek to transform neonatal care by protecting more preterm infants and improving their quality of life.

Vittoria Biotherapeutics is committed to unlocking the promise of cell therapies while addressing their inherent challenges by strengthening efficacy, improving safety, and broadening therapeutic applicability for patients with difficult-to-treat diseases. An Important Note About Privacy: Vittoria Biotherapeutics is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth, or bank account details via email, job recruiting, or social media platforms. We do not hire virtually or solicit/interview candidates on Indeed, Telegram, Wire, Google Hangouts or similar public platforms. Any questions about career opportunities can be directed to info@vittoriabio.com.

🧬🤖🖥 Vivodyne accelerates the discovery of cures to human diseases with highly scalable drug testing on lab-grown 3D human tissues.

Windtree Therapeutics is a global, clinical-stage, biopharmaceutical and medical device company focused on the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. Windtree has four clinical and multiple pre-clinical programs spanning respiratory, cardiovascular and oncology disease states. The Company’s lead clinical programs include AEROSURF®, a novel med-device combination designed to deliver the company’s proprietary synthetic, peptide-containing surfactant non-invasively to premature infants with respiratory distress syndrome (RDS); istaroxime, a first-in-class, dual-acting agent being developed to improve cardiac function in patients with acute heart failure while avoiding the unwanted side effects of existing treatments; and rostfuroxin, a novel precision medicine targeting hypertensive patients with certain genetic profiles focused on the large and important resistant hypertension market. In all we do, we are driven by compassion and the aspiration to help patients and their families realize the hope they have for a life less impacted by disease.

XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.

At Zynerba Pharmaceuticals, our team is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for patients affected by rare and near-rare neuropsychiatric conditions. Often, these diseases have few, if any, treatment options and can leave patients and their families feeling helpless and alone. Zynerba is committed to developing breakthrough therapies to transform the quality of lives of patients and their families as they battle these conditions. Our goal is to advance the science of therapeutic cannabinoids, and to improve the lives of patients battling severe neuropsychiatric conditions including Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD), 22q, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE). Our approach is to utilize our pharmaceutically-manufactured, penetration-enhanced transdermal cannabinoid product candidate to modulate pathways in the central nervous system that, when disrupted, cause certain neurological diseases. By doing so, we hope to provide new treatment options for patients battling certain rare neuropsychiatric diseases. Acquired by Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) on Oct. 11, 2023.